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The startle response is composed by a set of reflex behaviors intended to prepare
the organism to face a potentially relevant stimulus. This response can be modulated
by several factors as, for example, repeated presentations of the stimulus (startle
habituation), or by previous presentation of a weak stimulus (Prepulse Inhibition [PPI]).
Both phenomena appear disrupted in schizophrenia that is thought to reflect an
alteration in dopaminergic and glutamatergic neurotransmission. In this paper we
analyze whether the reported deficits are indicating a transient effect restricted to the
acute phase of the disease, or if it reflects a more general biomarker or endophenotype
of the disorder. To this end, we measured startle responses in the same set of thirteen
schizophrenia patients with a cross-sectional design at two periods: 5 days after
hospital admission and 3 months after discharge. The results showed that both startle
habituation and PPI were impaired in the schizophrenia patients at the acute stage
as compared to a control group composed by 13 healthy participants, and that PPI
but not startle habituation remained disrupted when registered 3 months after the
discharge. These data point to the consideration of PPI, but not startle habituation,
as a schizophrenia biomarker.
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INTRODUCTION
The information processing that is carried out by organisms with complex nervous systems begins
with a set of automatic processes of a preattentional nature that usually occur during the first
100 ms after the onset of the stimuli (Ellenbroek, 2004). These processes trigger various response
mechanisms, one category of which is the startle response, a neuronal mechanism related to
attention that varies along a continuum from deep sleep to intense excitement (Dawson et al.,
1999). The startle response includes a reflex including a startle and/or orienting response that is
evoked by a stimulus of sufficient intensity (Yeomans et al., 2002) and it reflects the activation
of motor tracts in the brainstem, particularly the bulbopontine reticular formation (Brown et al.,
1991). The basic physiological pattern of the acoustic startle reflex is mediated by a circuit involving
the statoacoustic nerve, the ventral cochlear nucleus, lateral lemniscus, nucleus reticularis pontis
caudalis, spinal interneuron, motor neurons of the anterior Horn, peripheral nerves, and muscles
(Davis et al., 1982; Lee et al., 1996).
The adaptive role of the startle reflex response is clear when we consider its plasticity in response
to various circumstances, which can lead to either an increase or decrease in its intensity. Thus, for
example, the startle response increases when the organism is in a state of emotional activation
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due to a process of sensitization (Thompson and Glanzman,
1976) or decreases with repeated presentations of a stimulus
due to the process of habituation (Tighe and Leaton, 1976).
A decline in the startle response is also observed when a stimulus
of low intensity precedes a more intense stimulus, a phenomenon
known as Prepulse Inhibition (PPI; Hoffman and Searle, 1968;
Graham and Murray, 1977).
The study of the startle response (and its plasticity) within
the field of schizophrenia has provided a wealth of information
concerning the possible biological and psychological processes
underlying this disorder (e.g., Braff et al., 2001a; Ludewig et al.,
2002). On the one hand, numerous studies focusing on the
habituation of the startle response in schizophrenia patients have
led to apparently contradictory results, since some studies have
identified a decrease in habituation of this response in patients
with schizophrenia (Geyer and Braff, 1982; Braff et al., 1992;
Parwani et al., 2000), whereas in other work, habituation appears
to remain intact (Braff et al., 1999; Kumari et al., 1999, 2002;
Cadenhead et al., 2000).
Some authors have suggested that, given that PPI can reflect
the ability to regulate the amount of sensory information that
is processed at all times, and that it plays a key role in filtering
relevant and irrelevant sensory information, alteration of this
effect in schizophrenia patients could be a cause of the overload
of sensory information that is characteristic of this disease (e.g.,
Perry and Braff, 1994). Indeed, a decline in PPI in schizophrenia
patients compared to healthy participants has been consistently
demonstrated in the literature (e.g., Braff et al., 1992, 1999;
Grillon et al., 1992; Kumari et al., 1999; Parwani et al., 2000;
Takahashi et al., 2008; Moriwaki et al., 2009), and it has thus
been proposed as a biomarker of the disease (e.g., Walters and
Owen, 2007; Light and Swerdlow, 2014). In particular, Gottesman
and Gould (2003) have proposed that PPI may be considered
a schizophrenia endophenotype, that is, a subtype of biomarker
that reflects the link between genetic and clinical expression (see,
also, Turetsky et al., 2007; Light et al., 2012).
The importance of identifying biomarkers of health becomes
apparent if we consider these to be objective indicators that can
provide information on the origin of the disorder, the prognosis,
and possible response to treatment (e.g., Light and Swerdlow,
2014). The notion of PPI as a biomarker for sensorimotor
gating in schizophrenia is supported not only by the changes
observed in schizophrenia patients, but also the increased
heritability observed in the decline in PPI in families with high
genetic vulnerability for schizophrenia (Hasenkamp et al., 2010;
Greenwood et al., 2016). Thus, for instance, Anokhin et al. (2003)
reported a 50% of PPI variance explained by genetic factors in a
sample of 142 female twins. Further, decreases in PPI have been
observed in asymptomatic first-degree relatives of schizophrenia
patients (Cadenhead et al., 2000), in patients with schizotypal
personality disorder (Cadenhead et al., 1993), and in healthy
subjects that score highly on tests designed to assess propensity
toward psychosis (Kumari et al., 2008). Finally, the stability across
time of PPI deficits in schizophrenia that is evident even before
the symptoms appear and that remains stable for as long as
2 years (Ziermans et al., 2011), or the growing evidence on
common genetic factors of PPI abnormalities and schizophrenia
(e.g., Roussos et al., 2016), support the notion of PPI as an
endophenotype of schizophrenia.
A critical aspect for determining the possible role of PPI
as a biomarker of the schizophrenic disorder is related to
the long-term stability of the PPI deficit in schizophrenia
patients. Evidence relating to this issue is still relatively scarce
and sometimes seemingly contradictory, since some researchers
have found that the PPI deficit remains constant over time
(Ludewig et al., 2002; Mackeprang et al., 2002; Duncan et al.,
2003; Düring et al., 2014), whilst in other studies, however,
it has been found that deficient PPI in schizophrenia patients
returned to normal levels when measurements were taken in
the chronic phase of the disorder (e.g., Meincke et al., 2004b;
Quednow et al., 2006; Minassian et al., 2007; Martinez-Gras et al.,
2009; Aggernaes et al., 2010; Hammer et al., 2011). Details of
longitudinal studies examining PPI in schizophrenia are listed
in Table 1. As it is evident from the findings described in
Table 1, deficits in PPI were consistently observed when PPI was
initially registered, irrespective of the stage of the disease (chronic
or acute). However, when PPI was retested in a follow up, it
remained disrupted in four reports but it was normalized in six
experiments.
On the basis of these considerations, the current paper has
three chief aims. The first is to confirm the attenuation of PPI in
patients diagnosed with schizophrenia compared with a control
sample of healthy participants. The second is to analyze the
possible impairment in habituation to the startle response in
schizophrenia patients. Finally, we aim to evaluate the persistence
and stability of these deficits in schizophrenia patients (both in
PPI and habituation of the startle response) by conducting a
retest 3 months after discharge. We expect to find attenuation of
both habituation of the startle response and PPI when comparing
the results of schizophrenia patients (in the acute phase of the
disease) with healthy controls. Moreover, if, as suggested by the
literature, the reduction in PPI is a biomarker for schizophrenia
and therefore remains stable over time, it is expected that this PPI
deficit would appear in the acute phase and would remain intact
3 months after discharge of the patients.
MATERIALS AND METHODS
Participants
Twenty-eight patients with a DSM-IV diagnosis of paranoid
schizophrenia, and 28 healthy controls matched for gender
and age, were initially enrolled at the inpatient services at the
Virgen del Rocío University Hospital, Seville (Spain). All patients
had been diagnosed by an experienced psychiatrist, and the
controls were screened for history of mental illness, drug and
alcohol abuse, or regular medical prescription. Of the initial
sample, 15 patients refused to participate in the follow up
assessment. Therefore, 13 schizophrenia patients (10 male, and
three female; mean age 37.31 years, range 21–61 years), and their
correspondent thirteen healthy controls (nine males and four
females; mean age 36.77, range; 21–60 years) were included in
the final sample. All patients had been admitted for psychotic
decompensation or psychotic episode. The startle testing for the
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TABLE 1 | Longitudinal studies of PPI in schizophrenia.
Participants Test–Retest Treatment
(Schizophrenia
sample)
PPI at T1 PPI at T2 (and T3)
Ludewig et al., 2002 Schizophrenia: 19
Control: 24
T1: Chronic
T2: 4 weeks
T3: 8 weeks
Mixed medication Reduceda Reduced
Mackeprang et al., 2002 Schizophrenia: 20
Control: 20
T1: Acute
T2: 12 weeks
Typical vs. Atypical Reduced Reducedb
Duncan et al., 2003 Schizophrenia: 15
Control: No
T1: Chronic
T2: 12 weeks
Mixed medication Reduced Reduced
Meincke et al., 2004b Schizophrenia: 36
Control: 18
T1: Acute
T2: 2–3 weeks
Mixed medication Reducedc Normalized
Quednow et al., 2006 Schizophrenia: 28
Control: 18
T1: Acute
T2: 4 weeks
T3: 8 weeks
Amisulpride vs.
Olanzapine
Reduced Normalizedd
Minassian et al., 2007 Schizophrenia: 23
Control: 20
T1: Acute
T2: 2 weeks
Mixed medication Reduced Normalized
Martinez-Gras et al., 2009 Schizophrenia: 45
Control: 36
T1: Chronic
T2: 12 weeks
Zuclopenthixol (T1)
vs. risperidone
(T29)
Reduced Normalized
Aggernaes et al., 2010 Schizophrenia: 16
Control: 14
T1: Acute
T2: 24 weeks
All quetiapine Reducede Normalized
Hammer et al., 2011 Schizophrenia: 13
Control: 17
T1: Acute
T2: 6 year
Mixed medication Reducedf Normalizedf
Düring et al., 2014 Schizophrenia: 51,
15
Control: 47
T1: Acute
T2: 2 weeks
T3: 6 weeks
All amisulpride Reduced Reduced
aPPI was reduced only at the 86 dB/60 ms condition. bPPI was restored irrespective of treatment with typical or atypical. cPPI was reduced only at the 73 dB/100 ms
condition. dPPI was restored irrespective of treatment with amisulpride or olanzapine. ePPI was reduced only for the males sample in the 85 Db/60 ms condition. fPPI
was reduced and normalized when the lead interval was 60 ms, but not with 30 or 120 ms.
TABLE 2 | Demographic and clinical characteristics of the participants.
Patients (acute) Patients (chronic) Controls
Male/Female 10/3 10/3 9/4
Age (years) 37.31 (13.31) 36.77 (12.38)
Age at onset (years) 25 (8.2)
Number of episodes 4.17 (2.99)
Smokers 10 5
PANSS-Positive 22.08 (5.37) 12.20 (3.88)
PANSS-Negative 16.42 (6.16) 15.20 (5.79)
PANSS-General 33.00 (9.66) 24.10 (8.20)∗∗
PANSS-Total 71.5 (15.88) 51.50 (16.46)∗
Medication
3 quetiapine 3 quetiapine
4 risperidone 2 risperidone
4 paliperidone 3 paliperidone
1 aripiprazole 1 aripiprazole
1 olanzapine 2 olanzapine
1 clozapine
1 untreated
Standard Deviations appear between brackets. PANSS scores were compared
at chronic vs. acute period (t-tests for related samples, one-tailed): ∗p < 0.05;
∗∗p < 0.001.
schizophrenia patients was conducted 3–8 days after admission to
hospital (acute stage) and 3 months after the discharge (chronic
stage), and mean number of days elapsed from the test at
the acute stage to discharge was 13.69 (SD = 9.88). Clinical
and demographic characteristics of the participants, including
Positive and Negative Syndrome Scale (PANSS) scores and
medication, are presented in Table 2. All patients were receiving
atypical antipsychotics before their inclusion in this experiment,
with doses between 300 and 750 mg/day (Chlorpromazine
equivalent), mean= 403.57 mg/day during the acute period, and
doses between 250–750 mg/day, mean = 349 mg/day during
the chronic period. PANNS General and Total scores were
significantly lower for the retest (chronic) as compared to the test
(acute) period. After being informed of the type of stimulation
used in the experiment, all subjects gave signed informed consent
to participate before to start the experimental manipulations
in accordance with the Declaration of Helsinki. This study
was carried out in accordance with the recommendations of
University of Seville’s ethical committee.
Procedure
Acoustic stimuli were delivered binaurally using adjustable
headphones (Sony model MDR-V50), connected to a MP150
control module (Biopac Systems Inc., Goleta, CA, USA). The
signal was sent with a high sampling rate of 50 kHz. The prepulse
and the pulse stimulus consisted of a 80 dB (A) and 106 dB
(A) white noise with instantaneous rise time, lasting for 20 and
50 ms, respectively. A background noise (white noise, 70 dB)
was presented during the entire duration of the experiment.
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Sound calibration was completed prior to record data for each
participant using a Sound Level Meter PCE-999.
The experiment was conducted in an isolated room. For
all auditory trials, the ITI was 15 s (+/− 5 s) and the lead
interval in prepulse-pulse trials was 40, 60, or 80 ms. After a
120 s adaptation period to the background noise, four pulses
were presented in order to establish the baseline response to
the auditory stimuli. Next, it started the experimental stage
composed by six blocks of four trials each that were presented
at random for each participant. Each block included two pulse-
alone and two prepulse-pulse trials. For two of the blocks the lead
interval for the prepulse-pulse trials was 40 ms, for other two
blocks it was 60 ms, and for the last two blocks it was 80 ms.
Finally, four pulse-alone trials were presented in order to check
habituation of the startle response.
Electromyographic (EMG) activity of the orbicularis oculi
muscle was recorded using three Ag/AgCl electrodes (EL250;
Biopac Systems) positioned according to the guidelines
recommended by Blumenthal et al. (2005). Specifically, after
cleaning the participant’s skin, conductive gel was applied to
the electrodes before placing two of them approximately 1 cm
below the right eye to record the EMG activity of the orbicularis
oculi muscle. The third electrode was placed on the forehead to
detect the general level of electrical activity. Raw signals were
amplified (×2000) and filtered using a passband of 10–500 Hz
(EMG100C amplifier; Biopac Systems). AcqKnowledge software
(4.0, Biopac Systems) was used to interface a MP150 control
module (Biopac Systems) via a cross-over cable and sampled at
2 kHz. Blink responses were considered valid when they occurred
between 21 and 120 ms after the pulse alone stimulus. Trials were
discarded when excessive EMG activity was observed during the
first 20 ms of recording. Less than 5% were discarded using these
parameters.
RESULTS
A preliminary analysis was conducted to evaluate the normality
of distributions of Startle and PPI scores (Shapiro–Wilk tests,
p < 0.05). Only startle magnitude to the Pulse-alone trials (Pre-
and Post-Experimental) for the acute Schizophrenia patients did
not follow the normal distribution. Therefore, those data were
explored with non-parametric test. The remaining analyses were
performed using ANOVAs.
Between Subjects Comparisons (Groups:
Acute Schizophrenia vs. Control)
Analysis of Startle Magnitude to the Pulse-alone
Trials
Figure 1 shows mean startle magnitude for the pre- and post-
experimental Pulse-alone trials (collapsed) registered during the
acute phase for the schizophrenia patients (middle section) and
the control participants (left section). As can be seen in the
Figure 1, startle habituation (indicated by a decrease in startle
magnitude from the pre- to the post-experimental period) was
only evident for the control group.
FIGURE 1 | Mean startle magnitude collapsed across trials for the
Pulse-alone trials presented before and after prepulse measurement
registered for the control participants (left section), for the
schizophrenia patients tested 3–7 days after admission (middle
section), and for the chronic patients tested 3 months after discharge
(right section). Error bars represent standard error of the mean. ∗P < 0.05;
∗∗p < 0.01 (see text for statistical details).
Since startle response to the Pre- and Post-experimental Pulse-
alone trials registered at the acute stage for schizophrenia patients
were not normally distributed, we used non-parametric Mann–
Whitney (independent samples) and Wilcoxon Signed-ranks
tests (related samples) to explore this variable. Startle magnitude
was similar for the Control and Schizophrenia participants at the
Pre-experimental period (U = 82.00, p > 0.89), but the startle
magnitude was more intense for the Schizophrenia patients than
for the Control participants at the post-experimental period
(U = 42.00, p < 0.05, respectively). Startle magnitude at Pre-
experimental period was significantly more intense as compared
to that registered at Post-experimental period for the Control
participants (Z = 3.18, p < 0.01), but not for the Schizophrenia
patients (Z = 1.15, p > 0.24). These results reveal that startle
magnitude was reduced across trials for the control participants
reflecting startle habituation, but habituation did not occur for
the acute schizophrenia patients.
Analyses of Percent PPI
Several studies have suggested that percent PPI is less
contaminated by individual differences than raw PPI (Hawk and
Cook, 2000). Accordingly, mean startle magnitudes for pulse and
prepulse-pulse trials were converted into percent PPI, calculated
as 100 × (Average startle to the pulse – Average startle to the
prepulse-pulse)/Average startle to the pulse. Since it has been
reported that differences in reactivity to pulse-alone stimulus can
influence percent PPI (e.g., Csomor et al., 2008), we conducted
a preliminary one-way ANOVA on mean startle intensity as
a function of Group that revealed the absence of differences
between the Control and the Acute Groups, F(1,24) < 1.
Figure 2 depicts mean percent PPI as a function of the 40, 60,
and 80 ms lead interval conditions for control and schizophrenia
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FIGURE 2 | Mean percent PPI as a function of Prepulse-Pulse interval
(40, 60, or 80 ms) for the control participants (left section), for the
schizophrenia patients tested 3–7 days after admission (middle
section), and for the chronic patients tested 3 months after discharge
(right section). Error bars represent standard error of the means. ∗P < 0.05
(see text for statistical details).
participants (PPI for patients registered at acute and chronic
periods). Attending to the between-subject comparison involving
PPI for Control (left section) vs. Acute schizophrenia (middle
section) participants that is depicted in Figure 2, PPI increased
across lead intervals, with higher PPI values for the 80 and 60 ms,
as compared to the 40 ms condition. In addition, the PPI effect
was reduced in the Acute schizophrenia patients as compared to
the control groups.
These impressions were confirmed by the statistical analyses.
A mixed 3 × 2 ANOVA (Lead interval: 40 vs. 60 vs.
80 ms × Group: Acute vs. Control) conducted on mean
percent PPI revealed significant main effects of Lead and
Groups, F(2,48) = 3.87; p < 0.05, and F(1,24) = 7.18;
p < 0.05, respectively. The two-way interaction was non-
significant, F(2,48) < 1. The main effect of Groups reflects a
higher overall percent PPI for the Control (Mean = 40.09%,
SD = 18.76) as compared to the Acute Group (Mean = 19.76%,
SD = 19.91). As for the significant effect of Lead interval, t-tests
for related samples (p < 0.05, one-tailed) were conducted on
mean percent PPI. The analysis revealed an overall higher PPI
for the 60 and 80 ms, (Mean = 33.21%, SD = 25.97, and
Mean = 33.99%, SD = 30.16, respectively) as compared to the
40 ms condition (Mean= 22.59%, SD= 18.66).
Within-Subject Comparisons (Acute vs.
Chronic)
Analysis of Startle Magnitude to the Pulse-alone
Trials
Figure 1 (right section) depicts mean startle magnitude for
the four Pulse-alone trials (collapsed) presented before and
after prepulse measurement recorded for the schizophrenia
participants during the chronic period (3 months after the
release). As can be seen in the figure, the startle response
magnitude and the habituation process were normalized at the
chronic period as compared to that observed at the acute period
(middle section of Figure 1).
Non-parametric Wilcoxon Signed-ranks tests (related
samples) revealed higher startle magnitude during the acute
as compared to the chronic stage both for the Pre- and the
Post-experimental periods (Z = 2.27, p < 0.05, and Z = 2.69,
p < 0.01, respectively). Interestingly, habituation of startle,
namely the reduction of startle intensity across Pulse-alone
presentations that did not appear at the acute period (Z = 1.15,
p > 0.24) was significant when registered at the chronic period
(Z = 2.69, p < 0.01).
Analyses of Percent PPI
Figure 2 (middle vs. right section) depicts mean percent of
PPI for schizophrenia patients as a function of the 40, 60,
and 80 ms lead interval conditions registered at the acute and
chronic periods. As can be seen in the figure, PPI remained
unchanged at the acute as compared to the chronic period for
all lead interval conditions. Consistently with this impression,
a mixed 3 × 2 ANCOVA conducted on mean percent PPI
(Lead interval: 40 vs. 60 vs. 80 ms × Group: Acute vs. Chronic,
both factors within-subject; chlorpromazine equivalent dose and
startle magnitude for the acute and chronic time points were
included as covariates) revealed non-significant main effects nor
interactions (all ps > 0.29).
Correlations between PANSS Scores and
PPI Magnitude
In order to analyze the relationship of symptoms in acute
and chronic stages with PPI magnitude, Pearson R correlations
were calculated between mean PPI for the 40, 60, and 80 ms
lead intervals and PANSS scores. There were no significant
correlations of PPI with any of the sub-scales of PANSS or total
PANSS score (all ps > 0.08).
DISCUSSION
Although taken with caution due to the small sample size1, the
analyses that compare the results of healthy control participants
with those obtained in acute schizophrenia patients have revealed
significant differences in both habituation of the startle response
and intensity of PPI. More specifically, participants without
pathologies showed normal habituation of the startle response
after repeated presentations of an intense auditory stimulus
(pulse), while for patients in acute phase the startle response
remained at the same intensity despite repeated presentations
of the stimulus. Some authors propose that this absence of
habituation of the startle response could serve as a trait marker
of schizophrenic psychoses (e.g., Meincke et al., 2004a). With
respect to the effect on PPI, our results reproduce those obtained
in the previous literature, since we observed a significant
reduction in the average percentage of PPI in acute schizophrenia
1In spite of the small sample size, the results can benefit from the specific a priori
hypotheses we have proposed, and the advantages of a within-subject design, with
lower error variability than similar between-subjects designs.
Frontiers in Behavioral Neuroscience | www.frontiersin.org 5 October 2016 | Volume 10 | Article 202
fnbeh-10-00202 October 15, 2016 Time: 11:54 # 6
Mena et al. Prepulse Inhibition and Schizophrenia
patients when compared with that observed in the healthy
control group. This data allows us to confirm that, at least
with the parameters used in our experiment, PPI appears to
be impaired in schizophrenia patients, a result that has been
well documented in previous literature (e.g., Meincke et al.,
2004b; Quednow et al., 2006; Minassian et al., 2007; Martinez-
Gras et al., 2009; Aggernaes et al., 2010; Hammer et al.,
2011).
With regard to the results reported in schizophrenia patients
3 months after discharge, once the symptoms had decreased, a
recovery of the process of habituation of the startle response
was observed, while the impairment in PPI remained unchanged
from that recorded in the acute stage of the disease. This
conclusion could be compromised by the lack of follow-up data
from control participants, since the level of habituation might
still be impaired in patients relative to controls at retest, and
PPI might have been also reduced in the control sample after
3 months. However, these possibilities are unlikely considering
that the improvement in startle habituation in schizophrenia is
based on a significant interaction between two within-subject
factors (Period: Pre- vs. Post-experimental and Schizophrenia
state: Acute vs. Chronic) supporting that the change of startle
habituation from the acute to the chronic period is a relevant
result by itself, independently of any hypothetical data from
control participants at follow-up. In addition, and regarding
the PPI result, the well-established high test–retest reliability
of PPI in healthy humans and schizophrenia patients (e.g.,
Abel et al., 1998; Flaten, 2002), allow us to anticipate that PPI
would have remained stable at retest for the control sample.
An additional potential factor that could have affected to the
data from the schizophrenia patients is related to the elevated
proportion of smokers in our sample (close to 80%). However,
it has been demonstrated that nicotine increases PPI in healthy
humans (e.g., Della Casa et al., 1998), in schizophrenia patients
(e.g., Hong et al., 2008), and in rodents (e.g., Pinnock et al.,
2015), but our data indicates that PPI was reduced for the
Schizophrenia patient’s sample. Therefore, we can discard an
effect of the smoking status on our results. There are also some
other limitations due to the lack of experimental control on
several factors that have demonstrated a relationship with startle
and PPI magnitude. Thus, we did not get SCID confirmation
of diagnoses, participants’ hearing acuity was not evaluated
before the experimental treatment, and time of menstrual
phase for female participants was not controlled. Especially,
the last factor has been related to PPI intensity, since it is
reduced in the luteal as compared to the follicular phase of
the menstrual cycle (Swerdlow et al., 1997; Jovanovic et al.,
2004). However, given the low number of female participants
in our sample (three in the schizophrenia patients group, and
four in the control group), we anticipate that the effect of
such variable may not have affected the results. In spite of the
mentioned limitations, our findings suggest that an attenuation
of PPI, but not the absence of habituation of the startle
response, may be considered as a biomarker of the schizophrenic
disorder.
The relevance of identifying biomarkers in the field of
mental illness, especially in the case of schizophrenic disorder,
has recently been highlighted by Light and Swerdlow (2014),
who note that PPI is one of the processes that meets the
criteria identified by two panels of experts that have gathered
in the past decade to identify the most appropriate therapies
for the treatment of cognitive processes in schizophrenia
patients: The Measurement and Treatment Research to Improve
Cognition in Schizophrenia (MATRICS; Green et al., 2004),
and the Cognitive Neuroscience Treatment Research to Improve
Cognition in Schizophrenia (CNTRICS; Carter et al., 2008). More
specifically, the criteria indicated by both initiatives as being
necessary to accept a measure as being a valid neurophysiologic
biomarker include, among other things, stability over time,
which is independent of state-related changes, the possibility
of conducting repeated measures, reactivity to pharmacological
treatment which can be reproduced in an animal model, and to
be associated with neural circuits and clearly identified cognitive
mechanisms (e.g., Green et al., 2009).
Of those criteria, our results provide evidence for the stability
of the deficit in PPI across different phases of schizophrenia,
an aspect of particular importance if we consider the lack of
conclusive evidence in previous literature. In particular, while
some studies have shown that disrupted PPI remains intact
independently of whether it is evaluated in schizophrenia patients
treated with traditional antipsychotics (Mackeprang et al., 2002;
Kunugi et al., 2007) or with atypical antipsychotics (Mackeprang
et al., 2002; Duncan et al., 2003), other work has shown a
recovery of PPI in schizophrenia after treatment with atypical
antipsychotics (Kumari et al., 1999; Leumann et al., 2002;
Oranje et al., 2002; Martinez-Gras et al., 2009). In our sample,
all patients were prescribed with atypical antipsychotics, but
the reduced PPI observed both in the acute and the chronic
periods indicates that the drug treatment was ineffective to
improve PPI. This result contrasts with some previous reports
indicating that patients medicated with the atypicals risperidone
(Mackeprang et al., 2002), clozapine (Oranje et al., 2002;
Kunugi et al., 2007) or long-acting risperidone (Martinez-Gras
et al., 2009) showed an improvement in sensorimotor gating.
It is worth noting, however, that in our sample only four
patients received risperidone at the acute stage (two at the
chronic period), and only one was prescribed with clozapine
at the chronic period, that can have reduced the impact
of medication on PPI normalization. Future research should
focus on differential effects of specific antipsychotic medication
of PPI taking advantage from within-subjects longitudinal
designs.
As we noted in the introduction, PPI has been proposed as
a model to detect differences in the processing of information
related to some structures and systems that are considered
essential in the development of schizophrenia, such as the
mesolimbic system or dopaminergic activity (e.g., Swerdlow et al.,
2001). From a cognitive standpoint, there is abundant evidence
that patients with schizophrenia have significant limitations both
in voluntary control of attention and control of the automatic,
preattentional processes that are responsible for limiting access
to irrelevant stimuli in order to process subsequent sensorimotor
integration (Braff et al., 1978). This process is essential for
adequate adaptation, since it allows selection of the most
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important elements of the environment and prevents overload of
sensory information that could contribute to disorders such as
those that characterize the occurrence of schizophrenia.
In our work we have provided direct evidence related to
the stability of PPI by collecting data at two different time
points separated by an interval of 3 months, using a test–retest
methodology. In spite of the difficulties in persuading patients
to agree to participate again in the collection of data after being
discharged, (which restricted the size of our participant sample),
we believe that the results are particularly relevant since for
the most part, the evidence available in the literature has been
obtained by indirect means such as comparing patient samples
with healthy participants (see, for reviews, Braff et al., 2001b;
Swerdlow et al., 2008).
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